These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11326654)

  • 1. Prostate-specific antigen (PSA) in the monitoring of prostate cancer after radical prostatectomy and external beam radiation.
    Schaefer U; Witt F; Schueller P; Micke O; Willich N
    Anticancer Res; 2000; 20(6D):4989-92. PubMed ID: 11326654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer.
    Schaefer U; Micke O; Willich N
    Anticancer Res; 1999; 19(4A):2645-8. PubMed ID: 10470211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Cozzarini C; Montorsi F; Fiorino C; Alongi F; Bolognesi A; Da Pozzo LF; Guazzoni G; Freschi M; Roscigno M; Scattoni V; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):966-74. PubMed ID: 19619960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant radiotherapy in locally confined prostate cancer.
    Schäfer U; Witt F; Micke O; Willich N
    Anticancer Res; 2003; 23(2A):983-5. PubMed ID: 12820335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
    J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of radiotherapy on patients with prostate specific antigen failure after radical prostatectomy].
    Sakata Y; Hasegawa Y; Wakita T; Hayashi N; Fuwa N
    Hinyokika Kiyo; 2004 Jul; 50(7):463-7. PubMed ID: 15334889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.
    Schild SE; Buskirk SJ; Wong WW; Halyard MY; Swanson SK; Novicki DE; Ferrigni RG
    J Urol; 1996 Nov; 156(5):1725-9. PubMed ID: 8863580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.